PL2277890T3 - Peptyd zdolny do wydłużenia czasu półtrwania w osoczu peptydu będącego przedmiotem zainteresowania - Google Patents

Peptyd zdolny do wydłużenia czasu półtrwania w osoczu peptydu będącego przedmiotem zainteresowania

Info

Publication number
PL2277890T3
PL2277890T3 PL09750669T PL09750669T PL2277890T3 PL 2277890 T3 PL2277890 T3 PL 2277890T3 PL 09750669 T PL09750669 T PL 09750669T PL 09750669 T PL09750669 T PL 09750669T PL 2277890 T3 PL2277890 T3 PL 2277890T3
Authority
PL
Poland
Prior art keywords
peptide
interest
plasma
life
extending half
Prior art date
Application number
PL09750669T
Other languages
English (en)
Inventor
Naomi Wakabayashi
Seiji Sato
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of PL2277890T3 publication Critical patent/PL2277890T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/63—Motilins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
PL09750669T 2008-05-23 2009-05-22 Peptyd zdolny do wydłużenia czasu półtrwania w osoczu peptydu będącego przedmiotem zainteresowania PL2277890T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008136106 2008-05-23
PCT/JP2009/059464 WO2009142307A1 (ja) 2008-05-23 2009-05-22 目的ペプチドの血漿中半減期延長作用を有するペプチド
EP09750669.5A EP2277890B1 (en) 2008-05-23 2009-05-22 Peptide capable of extending half-life of peptide of interest in plasma

Publications (1)

Publication Number Publication Date
PL2277890T3 true PL2277890T3 (pl) 2016-06-30

Family

ID=41340233

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09750669T PL2277890T3 (pl) 2008-05-23 2009-05-22 Peptyd zdolny do wydłużenia czasu półtrwania w osoczu peptydu będącego przedmiotem zainteresowania

Country Status (16)

Country Link
US (1) US8551937B2 (pl)
EP (1) EP2277890B1 (pl)
JP (1) JP5524049B2 (pl)
KR (2) KR20130018965A (pl)
CN (1) CN101809029B (pl)
BR (1) BRPI0904622A2 (pl)
CA (1) CA2698582C (pl)
CY (1) CY1117478T1 (pl)
DK (1) DK2277890T3 (pl)
ES (1) ES2566830T3 (pl)
HR (1) HRP20160303T1 (pl)
HU (1) HUE028539T2 (pl)
PL (1) PL2277890T3 (pl)
PT (1) PT2277890E (pl)
SI (1) SI2277890T1 (pl)
WO (1) WO2009142307A1 (pl)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005235635B2 (en) 2004-04-21 2010-11-18 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
KR102033680B1 (ko) * 2009-05-20 2019-10-18 바이오마린 파머수티컬 인크. 씨형 나트륨이뇨 펩티드의 변이체
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
EP2682128B1 (en) 2011-02-28 2017-11-08 National Cerebral and Cardiovascular Center Atrial natriuretic peptide or brain natriuretic peptide for use in preventing metastasis
WO2013027680A1 (ja) 2011-08-19 2013-02-28 独立行政法人国立循環器病研究センター ナトリウム利尿ペプチド受容体gc-aアゴニスト及びgc-bアゴニストを組み合わせてなる悪性腫瘍の増悪防止用医薬
JPWO2013099376A1 (ja) * 2011-12-26 2015-04-30 国立大学法人福井大学 体外受精における成熟卵子マーカー及びその使用
JPWO2013161895A1 (ja) * 2012-04-25 2015-12-24 第一三共株式会社 骨修復促進剤
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
TW201442721A (zh) 2013-01-23 2014-11-16 Daiichi Sankyo Co Ltd 糖鏈修飾心房利尿鈉肽
JPWO2015129812A1 (ja) * 2014-02-27 2017-03-30 第一三共株式会社 ステロイド剤投与で誘発される成長障害に対する医薬
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
JP6946182B2 (ja) 2014-10-22 2021-10-06 エクステンド バイオサイエンシズ インコーポレーテッドＥｘｔｅｎｄ Ｂｉｏｓｃｉｅｎｃｅｓ， Ｉｎｃ 治療用ビタミンｄコンジュゲート
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
KR20170095278A (ko) 2014-12-05 2017-08-22 알렉시온 파마슈티칼스, 인코포레이티드 재조합 알칼리성 포스파타제를 이용한 발작 치료
AU2016211447B2 (en) 2015-01-28 2021-09-23 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
WO2017031114A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
PL3400019T3 (pl) * 2016-01-08 2023-01-23 Ascendis Pharma Growth Disorders A/S Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
US11186832B2 (en) 2016-04-01 2021-11-30 Alexion Pharmaceuticals, Inc. Treating muscle weakness with alkaline phosphatases
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
US20190218274A1 (en) * 2016-05-06 2019-07-18 Phasebio Pharmaceuticals, Inc. Elp fusion proteins for controlled and sustained release
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
US20200030414A1 (en) 2017-01-24 2020-01-30 Daiichi Sankyo Company, Limited Therapeutic agent for short stature
WO2018175534A1 (en) * 2017-03-22 2018-09-27 Pharmain Corporation Npra agonists, compositions, and uses thereof
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
JP7378839B2 (ja) * 2018-12-26 2023-11-14 スキンメドカンパニーリミテッド アセチルコリン受容体阻害ペプチド及びその用途
MX2021015160A (es) 2019-06-12 2022-03-17 Novartis Ag Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3026354B2 (ja) * 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
US20060263382A1 (en) * 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
PT1795598E (pt) 1999-07-23 2010-01-05 Kenji Kangawa Novos péptidos
CN101177455A (zh) * 2001-08-30 2008-05-14 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
ATE490969T1 (de) 2001-08-30 2010-12-15 Biorexis Pharmaceutical Corp Modifizierte transferrin-fusionsproteine
CN101312745A (zh) 2005-11-21 2008-11-26 国立大学法人宫崎大学 包含生长素释放肽或其衍生物或作用于GHS-R1a的物质作为活性成分的皮肤修复促进治疗剂
KR20080082651A (ko) * 2005-11-21 2008-09-11 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 데스아실 그렐린 및 그 유도체를 유효 성분으로 하는 피부수복 촉진 치료제
WO2008018600A1 (fr) * 2006-08-11 2008-02-14 University Of Miyazaki AGENT THÉRAPEUTIQUE PERMETTANT D'ACCÉLÉRER LA RÉPARATION DES NERFS RACHIDIENS COMPRENANT EN TANT QUE MATIÈRE ACTIVE DE LA GHRÉLINE, UN DÉRIVÉ DE CELLE-CI OU UNE SUBSTANCE CAPABLE D'AGIR SUR LE GHS-R1a
AU2007282428A1 (en) * 2006-08-11 2008-02-14 Asubio Pharma Co., Ltd. Spinal nerve repair promoting therapeutics containing des-acyl ghrelin or its derivatives as an active ingredient
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks

Also Published As

Publication number Publication date
CN101809029A (zh) 2010-08-18
ES2566830T3 (es) 2016-04-15
DK2277890T3 (en) 2016-02-08
KR20100038236A (ko) 2010-04-13
PT2277890E (pt) 2016-03-31
CN101809029B (zh) 2016-06-15
JP5524049B2 (ja) 2014-06-18
US20100305031A1 (en) 2010-12-02
HUE028539T2 (en) 2016-12-28
KR101350251B1 (ko) 2014-01-14
EP2277890A4 (en) 2011-08-24
CA2698582C (en) 2016-09-13
BRPI0904622A2 (pt) 2016-06-21
WO2009142307A1 (ja) 2009-11-26
SI2277890T1 (sl) 2016-04-29
EP2277890B1 (en) 2016-01-06
CY1117478T1 (el) 2017-04-26
HRP20160303T1 (hr) 2016-04-22
EP2277890A1 (en) 2011-01-26
JPWO2009142307A1 (ja) 2011-09-29
KR20130018965A (ko) 2013-02-25
CA2698582A1 (en) 2009-11-26
US8551937B2 (en) 2013-10-08

Similar Documents

Publication Publication Date Title
SI2277890T1 (sl) Peptid, sposoben podaljšanja razpolovne dobe peptida, ki je zanimiv, v plazmi
HK1250042A1 (zh) 溶酶體靶向肽及其應用
EP2373679A4 (en) HEPPIDINE MINI PEPTIDES AND METHODS OF USE
GB0914110D0 (en) Peptide libraries
GB0913775D0 (en) Multispecific peptides
EP2249853A4 (en) PEPTIDE PRODRUGS BASED ON ESTERS
HK1214177A1 (zh) 用於癌症的肽治療劑
PL2421884T3 (pl) Aktywatory proteasomowe w formie hydrolizatu peptydowego i zawierające je kompozycje
EP2346521A4 (en) PEPTIDES AND METHODS OF USE
IL216223A0 (en) Methods of analyzing peptide mixtures
EP2373272A4 (en) STALL ARTICLE
TWI319863B (en) Plasma display
GB0920981D0 (en) Peptides
EP2270141A4 (en) Lacritin PART PEPTIDE
HK1217912A1 (zh) 控釋肽製劑
EP2123666A4 (en) PEPTIDE
EP2478010A4 (en) PART PEPTIDE OF LACRITINE
EP2285827A4 (en) PEPTIDES AND ITS USE
GB0724953D0 (en) Methods of peptide modification
IL216199A (en) A peptide containing the sequence ednimvtfrnqasr
HK1151242A1 (en) Mntf peptide compositions and methods of use mntf
ZA201203722B (en) Peptide
EP2504065A4 (en) STABLE MIXTURES AND RELATED METHODS
EP2188305A4 (en) MODIFIED PEPTIDES HAVING TOXIN IMPROVING EFFECTS
GB0703945D0 (en) Peptide